Lv2
110 积分 2021-10-28 加入
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
27天前
已完结
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
1个月前
已完结
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
1个月前
已完结
Novel Dihydroisoquinolinone-Amide Compounds as GIPR Agonists for Treating Type 2 Diabetes Mellitus and Obesity
2个月前
已关闭
The Multi-Faceted Landscape of TEAD Inhibition: a 2017–2025 Patent and Literature Review
2个月前
已完结
Synthesis and Biological Evaluations of Novel Human Parathyroid Hormone 1 Receptor (hPTHR1) Agonists Bearing Bicyclic Aromatic Moiety
6个月前
已完结
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
7个月前
已完结
Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity
8个月前
已完结
Design, Synthesis and Biological Evaluation of Novel, Potent, Selective and Orally Available DGKα Inhibitors for the Treatment of Tumors
8个月前
已完结
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
9个月前
已完结
皖公网安备34019202002308
